Inhibrx Biosciences Inc. (INBX)
14.02
-0.03 (-0.21%)
At close: Apr 02, 2025, 3:59 PM
14.10
0.57%
After-hours: Apr 02, 2025, 04:12 PM EDT
-0.21% (1D)
| Bid | 13.2 |
| Market Cap | 202.95M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | n/a |
| EPS (ttm) | 112.62 |
| PE Ratio (ttm) | 0.12 |
| Forward PE | -1.82 |
| Analyst | n/a |
| Ask | 14.81 |
| Volume | 187,088 |
| Avg. Volume (20D) | 110,758.5 |
| Open | 13.76 |
| Previous Close | 14.05 |
| Day's Range | 13.53 - 14.18 |
| 52-Week Range | 10.80 - 18.95 |
| Beta | -1.11 |
About INBX
Inhibrx Biosciences, Inc., a clinical-stage biopharmaceutical company, engages in the development of biologic therapeutics for people with life-threatening conditions. Its therapeutic candidates includes INBRX-109, a tetravalent therapeutic candidate targeting death-receptor 5 that is in phase 2 clinical trial for the treatment of unresectable or metastatic conventional chondrosarcoma; and INBRX-106, a hexavalent sdAb-based therapeutic candidate ...
Industry Biotechnology
Sector Healthcare
IPO Date Jun 4, 2024
Employees 156
Stock Exchange NASDAQ
Ticker Symbol INBX
Website https://inhibrx.com
4 months ago · seekingalpha.com
Inhibrx Biosciences: Reincorporated And Trying To Find A Niche With Unique PlatformINBX's two main pipeline candidates, INBRX-109 and INBRX-106, are entering critical late-stage trials with data readouts expected in mid- to late-2025. INBRX-109 targets DR5 in solid tumors, showing p...